10-K/A: VSee Health Restates Financials, Faces Going Concern Doubt

VSee Health, Inc. filed an amended annual report for 2024, restating prior financials, reporting a significant net loss driven by goodwill impairment, and disclosing substantial doubt about its ability to continue as a going concern.

Summary

• VSee Health, Inc. (formerly Digital Health Acquisition Corp.) filed an amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024, which includes a comprehensive restatement of previously issued financial statements for 2023 and interim periods of 2023 and 2024.
• The restatement was necessary due to errors in the recognition and measurement of accrued expenses (including sales and use taxes) and revenue transaction cutoffs, as well as issues related to the business combination date.
• The company reported a net loss of $57,702,015 for the year ended December 31, 2024, a significant increase from $3,725,454 in 2023.
• This substantial loss was primarily driven by goodwill impairment charges of $56,675,210 recognized in 2024.
• Revenue increased by 81% to $10,421,352 in 2024 from $5,765,889 in 2023, largely due to the acquisition of iDoc and higher technical and engineering fees.
• Operating expenses surged by 1,115% to $69,328,425 in 2024, mainly due to the goodwill impairment, increased general and administrative expenses, and higher transaction costs related to the business combination.
• The company has an accumulated deficit of $67,703,873 as of December 31, 2024, and experienced operating cash outflows of $5,789,542 for the year.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least one year from the financial statement issuance date.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting personnel, ineffective IT General Controls, lack of a formalized control environment, and improper accounting for significant transactions, contributing to the late filing and restatement.
• The company received a delisting notice from Nasdaq on April 25, 2025, for failing to timely file its 10-K and subsequent 10-Q reports, with an appeal hearing scheduled for September 9, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including a substantial net loss driven by goodwill impairment, an accumulated deficit, negative cash flows, and a going concern warning. Material weaknesses in internal controls and a Nasdaq delisting notice further highlight significant operational and compliance challenges. While revenue growth is positive, it is overshadowed by these critical issues.

Positives

• Revenue increased by 81% to $10,421,352 in 2024, driven by the iDoc acquisition and growth in technical and engineering fees.
• The acquisition of iDoc contributed $2,217,733 (49%) to revenue in 2024, expanding the company's high-acuity patient care solutions.
• Technical and engineering fees increased by 201% ($1,322,218) due to a higher volume of services for new and existing clients.
• Professional and other fees increased by 98% ($1,045,193) from higher project management services and patient visits.
• The company's telehealth platform (VSee Lab) offers comprehensive, configurable, HIPAA, SOC2, and GDPR compliant solutions, positioning it well in the evolving market.
• iDoc provides specialized intensive care unit services and e-consults, addressing a shortage of intensivists and physician burnout.
• New contracts with larger hospitals and entry into new markets demonstrate the company's ability to generate positive revenue growth.
• The company has an Equity Line of Credit (ELOC) for up to $50,000,000, providing a potential source of future capital.

Negatives

• Net loss significantly increased by 1,449% to $57,702,015 in 2024 from $3,725,454 in 2023.
• Goodwill impairment charges of $56,675,210 were a primary driver of the increased net loss in 2024.
• The company has an accumulated deficit of $67,703,873 as of December 31, 2024.
• Operating cash outflows were $5,789,542 for the year ended December 31, 2024.
• A working capital deficit of $15,989,353 existed as of December 31, 2024, with current cash insufficient for 12 months of operating needs.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting personnel, ineffective ITGCs, and lack of formalized control oversight.
• The company received a delisting notice from Nasdaq on April 25, 2025, for failure to timely file required reports, and faces potential suspension of trading.
• The restatement of previously issued financial statements indicates past accounting errors and could affect investor confidence.
• Operating expenses increased by 1,115% in 2024, largely due to non-cash goodwill impairment and higher professional fees related to the business combination.

Risks

• The restatement of previously issued financial statements and associated remedial measures have been time-consuming and expensive, potentially exposing the company to additional risks.
• There is substantial doubt regarding the company's ability to continue as a going concern, which could lead to a loss of investment.
• The company operates in a rapidly evolving and highly competitive telemedicine market, facing competition from established players and large technology/retail companies.
• Demand for and market utilization of the company's software and solutions are subject to a high degree of uncertainty, and the market may develop slower than expected.
• The company expects to incur future losses and may not achieve or sustain profitability, potentially requiring additional dilutive financing.
• The developing nature of the business and markets makes it difficult to evaluate the business and its prospects.
• Operating results may fluctuate significantly on a quarterly and annual basis, potentially leading to stock price declines.
• Sales cycles can be long and unpredictable, requiring considerable time and expense without guaranteed sales.
• Developments affecting spending by the healthcare industry, such as government regulations or consolidation, could adversely affect revenues.
• Medical malpractice risks are inherent in the provision of healthcare services, potentially leading to substantial costs and reputational harm.
• Economic uncertainties or prolonged downturns could disproportionately affect demand for solutions and harm the business.
• Failure to retain existing clients, renew contracts at favorable terms, or sell additional services could harm revenues.
• The company's growth strategy depends on maintaining and expanding its network of physicians and provider specialists, which may be challenging.
• Dependence on relationships with affiliated professional entities to provide medical services poses a risk if these relationships are disrupted or found to violate corporate practice of medicine laws.
• Failure to develop and release new solutions or enhancements in a timely manner could harm the business and market share.
• Inability to offer high-quality technical support services could damage client relationships and financial results.
• Intense competition for qualified personnel, especially highly skilled employees in the healthcare market, could limit growth.
• Loss of senior management team members or inability to attract/retain key personnel could harm the business.
• Management's broad discretion in strategic decisions may not always result in successful achievement of business objectives.
• Acquisitions of other companies or technologies could divert management's attention, result in dilution, disrupt operations, and be difficult to integrate.
• Failure to manage future growth effectively could lead to unexpected expenses, inability to meet client requirements, and decreased revenues.
• Inaccurate estimates and assumptions used to determine the total addressable market could affect future growth rates.
• The company may not grow at historical rates, even if key metrics indicate growth, adversely affecting stock price.
• Future litigation could be costly, time-consuming, and divert management's attention.
• Taxing authorities may successfully assert that the company should have collected sales and use or similar taxes, leading to past or future liabilities.
• The company will likely require additional capital from equity or debt financings, which may not be available on acceptable terms or at all, leading to significant dilution.
• The price of common stock and public warrants may be volatile, resulting in substantial losses for investors.
• Failure to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements.
• As an emerging growth company, reduced disclosure requirements may make securities less attractive to investors.
• The lack of substantial combined operating history between VSee Lab and iDoc makes successful integration uncertain.
• The current management team has no prior experience managing a public company, posing risks related to regulatory oversight and public scrutiny.
• Restatement of financial statements may affect investor confidence and raise reputational issues.
• Failure to meet Nasdaq listing requirements could lead to delisting, reduced liquidity, and decreased ability to raise future financing.
• Terms of public warrants may be amended adversely to holders with majority approval.
• Holders of convertible promissory notes may sell large numbers of shares, causing substantial dilution and stock price decline.
• FDA regulatory review and oversight may apply to certain software products, requiring compliance.
• FTC oversees advertising and promotion, requiring scientific data to substantiate claims.
• Reliance on telecommunications and internet service providers means interruptions or failures could harm the business.
• Failure to protect or enforce intellectual property rights could impair the ability to protect technology and brand.
• Software platforms may not perform properly due to errors, damaging reputation or giving rise to claims.
• Currently lacks formalized cybersecurity measures, dedicated team, or specific protocols, leaving it vulnerable to cyberattacks and data breaches.

Future Outlook

Management believes the rapid transformation of the telehealth market indicates strong future growth and that current offerings provide an attractive value proposition. The company plans to continue harnessing its scale to grow the platform's value proposition and leverage industry relationships to expand its customer base. Future success depends on the ability to invest in new technology and develop new features, modules, and solutions. Management's plan to alleviate going concern doubts includes revenue enhancement strategies, such as new contracts with larger hospitals and market expansion, and securing additional working capital through public or private equity or debt financings, including utilizing its $50,000,000 Equity Line of Credit.

Management Comments

• Management has concluded that substantial doubt exists about our ability to continue as a going concern for one year after the date our consolidated financial statements are issued.
• We expect our costs will increase in the foreseeable future and we may incur losses.
• We also expect to invest significant additional funds towards enhancing our services and platform, growing our business and operating as a public company.
• We believe that the rapid transformation of the telehealth market indicates strong future growth of the market, and our current offerings provide an attractive value proposition to health systems, medical groups, and individual medical practitioners, driving higher market share.
• We plan to continue to harness our scale to further grow the value proposition of our platform for all stakeholders.
• We believe our ability to invest in new technology and develop new features, modules, and solutions will be critical to our long-term success.
• We lack the resources to employ additional personnel to help mitigate these material weaknesses and we foresee that these material weaknesses will not be remediated until we receive additional funding to support our accounting department.

Industry Context

The telehealth market is characterized by rapid transformation, with major customers and hospital systems seeking to build or enhance capabilities, and legacy competitors addressing historical limitations. The industry faces challenges such as a shortage of nurses and physicians, increasing complexity in intensive care units, and the need for better patient engagement and clinician staffing options. The company's no-code/low-code platform and specialized ICU services are designed to address these trends, aiming to empower clinicians and bridge care gaps. However, the market is highly competitive, with new entrants and large technology/retail companies developing their own virtual care solutions, leading to pricing pressures.

Comparison to Industry Standards

• The company competes with established telehealth providers like MDLive (Cigna), American Well Corporation, Included Health, and Accolade, Inc., as well as specialized neuro/ICU competitors such as NeuroCall, Ceribell, and Specialist on Call.
• VSee's no-code/low-code approach to telehealth configuration is presented as an advantage over more rigid EMR-built telehealth tools and general video conferencing software (e.g., Zoom, Microsoft Teams), which often lack healthcare-specific productivity and patient engagement features.
• The iDoc platform differentiates itself from hardware-centric competitors by focusing on optimizing an extensive network of board-certified physicians and highly configurable workflows.
• The company believes its solutions meet performance and compliance standards in healthcare, offering more comprehensive telehealth care than many existing video-only tools by integrating medical device data and EMRs.
• Despite rapid advancements, telehealth technology solutions have not fully penetrated medicine and hospital systems, representing less than 1% of total healthcare spending, indicating a significant market opportunity for companies like VSee Health that can overcome existing limitations.

Management Changes

Corporate Governance

Legal Proceedings

• The company was not a party to any material legal proceedings as of the filing date.
• On July 25, 2024, the company was notified of a lawsuit alleging breach of contract and unjust enrichment, seeking payment under promissory notes and the Encompass Acquisition Agreement.
• The company filed a counterclaim for breach of contract, promissory estoppel, and unjust enrichment.
• Settlement discussions are actively ongoing, but the range of potential loss cannot be reasonably estimated.

Related Party Transactions

• On October 4, 2023, DHAC issued an unsecured promissory note of $165,000 to M2B (an affiliate of the Sponsor), which was satisfied on January 31, 2024.
• Loans incurred by VSee Lab to the Bridge Investor (an investor in the Sponsor) totaling $600,000 were converted into Common Stock following the Business Combination.
• Loans incurred by iDoc to Tidewater Ventures, LLC (a Sponsor Affiliate) totaling $585,000 were converted into Common Stock following the Business Combination.
• Loans incurred by iDoc to the Bridge Investor totaling $600,000 were converted into Common Stock following the Business Combination.
• On December 31, 2024, the company entered into the Ascent Purchase Agreement with Ascent (an affiliate of the Bridge Investor) for a $2,000,000 secured convertible promissory note.
• On November 8, 2024, SCS, LLC (an affiliate of the Sponsor) converted $405,000 of working capital advances into 202,500 shares of Common Stock, treated as a troubled debt restructuring with a gain recorded to additional paid-in capital.
• As of December 31, 2024, $51,900 of advances due to the Sponsor and certain Sponsor affiliates remained due and payable.
• On June 21, 2024, the company entered a Consulting Services Agreement with SCS, LLC, for $12,500 per month for business consulting and $2,500 per month for office space, plus initial and future stock issuances.
• The Quantum Convertible Note ($3,000,000 principal) was issued to the Quantum Investor, in which SCS Capital Partners LLC (a Sponsor affiliate) owns approximately 40.74%.
• On March 28, 2024, iDoc issued a $224,000 secured convertible promissory note to David L. Wickersham, who later became a director, which was paid off by issuing 114,000 shares of common stock.
• VSee Lab received promissory notes from its then CEO, Milton Chen, for $121,000 and $132,000 in March 2023, and $77,000 in December 2023.
• A related party balance of $531,656 was due from iDoc's then CEO, Imoigele Aisiku, as of December 31, 2024.
• A note receivable of $336,000 from iDoc's then CEO, Imoigele Aisiku, was written off in 2024.
• iDoc had a $200,000 promissory note with a board member, with payments based on monthly revenue from telepresence robots.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and potential future equity financings, including convertible notes and the ELOC. The substantial net loss, goodwill impairment, and going concern warning could lead to further stock price decline. The Nasdaq delisting notice poses a severe risk to liquidity and market value.
• **Employees**: The company's ability to attract and retain highly skilled personnel, including physicians and software engineers, is critical for growth but challenged by intense competition. The material weaknesses in internal controls and financial instability could impact employee morale and retention.
• **Customers (Hospitals and Enterprises)**: Benefit from the company's comprehensive telehealth platform and specialized ICU services, which aim to improve patient engagement, address clinician shortages, and reduce costs. However, concerns about the company's financial stability and operational controls could impact service reliability and long-term partnerships.
• **Suppliers/Creditors**: Face increased risk due to the company's going concern doubt and accumulated deficit. The default status on some notes payable and the need for additional financing indicate potential challenges in timely payments.
• **Regulatory Bodies**: The SEC is involved due to the restatement and late filings. The company is subject to extensive healthcare regulations (HIPAA, Anti-Kickback, False Claims) and data privacy laws, with non-compliance potentially leading to fines and penalties. Nasdaq is actively reviewing the company's listing status.

Next Steps

• Management plans to alleviate going concern doubts by raising additional working capital through public or private equity or debt financings.
• The company may undertake cost-cutting measures, including delaying or discontinuing certain operating activities, if adequate financing is not secured.
• The company intends to continue to take steps to enhance its internal controls, including providing enhanced access to accounting literature, research materials, and increased communication among personnel and third-party professionals.
• An appeal hearing before the Nasdaq Hearings Panel is scheduled for September 9, 2025, to address the delisting notice.
• The company is evaluating its cybersecurity needs and developing appropriate measures, including considering external cybersecurity experts and an incident response strategy.
• The Board of Directors will oversee the cybersecurity risk management framework and a dedicated committee or officer will review and approve cybersecurity policies.
• The company is currently assessing the impact of the One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements, with provisions effective in 2025 and through 2027.
• The company is evaluating the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses) and ASU 2025-05 (Credit Losses for Accounts Receivable) for adoption in future fiscal years.

Key Dates

Recommendation

The filing reveals a company in severe financial distress. The substantial net loss of over $57 million, primarily due to a massive goodwill impairment, indicates significant asset value destruction. The accumulated deficit of $67.7 million and negative operating cash flows raise 'substantial doubt' about the company's ability to continue as a going concern, a critical red flag for investors. Furthermore, the identification of material weaknesses in internal controls over financial reporting and the receipt of a Nasdaq delisting notice for failure to file timely reports point to severe operational and governance deficiencies. While revenue growth is present, it is entirely overshadowed by these fundamental issues. The need for continuous capital raises, often on unfavorable terms, suggests ongoing dilution for existing shareholders. Given the high risk of delisting, continued losses, and fundamental control issues, a seasoned investor would likely recommend a strong sell to minimize further losses.

Keywords

Telehealth, Digital Health, SEC Filing, 10-K/A, Financial Restatement, Going Concern, Goodwill Impairment, Healthcare Technology, Telemedicine, ICU Services, Patient Engagement, Clinician Staffing, Remote Patient Monitoring, AI in Healthcare, Corporate Governance, Nasdaq Delisting, Capital Raise, VSee Health, iDoc, Financial Reporting, Risk Management